INDEPENDENT NEWS

Munchkin US FDA Process on hold

Published: Thu 16 May 2019 01:52 PM
SYNLAIT MILK LIMITED ANNOUNCEMENT NZX: SML
ASX: SM1
16 May 2019
MUNCHKIN U.S. FDA PROCESS ON HOLD
The U.S. Food and Drug Administration (FDA) registration process required to launch Munchkin’s Grass Fed™ infant formula in the U.S. has been put on hold.
Synlait (NZX: SML; ASX: SM1) has been informed that the clinical study has been put on hold to allow Munchkin to explore other options in the U.S.
“Munchkin has not terminated its supply agreement with Synlait. For other markets where Grass Fed™ is sold the relationship continues with business as usual,” says Synlait CEO, Leon Clement.
The development will not have a material impact on Synlait’s forecast infant formula volumes.
ENDS

Next in Business, Science, and Tech

Massive Rebound In Civil Construction Business Confidence
By: Civil Contractors NZ and Teletrac Navman
Feeling Our Way Towards Hydrogen - Tina Schirr
By: Business NZ
Maritime Union Calls For New Zealand Shipping To Resolve Supply Chain Crisis
By: Maritime Union of New Zealand
New Home Consents Continue To Break Records
By: Statistics New Zealand
June Home Transfers Remain High
By: Statistics New Zealand
Household Saving Falls In The March 2021 Quarter
By: Statistics New Zealand
New Data Shows Household Net Worth Increases On The Back Of Rising Asset Values
By: Statistics New Zealand
View as: DESKTOP | MOBILE © Scoop Media